Automated Dashboards for the Identification of Pathogenic Circulating Tumor DNA Mutations in Longitudinal Blood Draws of Cancer Patients.
Aleksandr UdalovLexman KumarAnna N GaudetteRan ZhangJoao SalomaoSanjay SaigalMehdi NosratiSean D McAllisterPierre-Yves DesprezPublished in: Methods and protocols (2023)
The longitudinal monitoring of patient circulating tumor DNA (ctDNA) provides a powerful method for tracking the progression, remission, and recurrence of several types of cancer. Often, clinical and research approaches involve the manual review of individual liquid biopsy reports after sampling and genomic testing. Here, we describe a process developed to integrate techniques utilized in data science within a cancer research framework. Using data collection, an analysis that classifies genetic cancer mutations as pathogenic, and a patient matching methodology that identifies the same donor within all liquid biopsy reports, the manual work for research personnel is drastically reduced. Automated dashboards provide longitudinal views of patient data for research studies to investigate tumor progression and treatment efficacy via the identification of ctDNA variant allele frequencies over time.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- papillary thyroid
- electronic health record
- squamous cell
- case report
- big data
- machine learning
- copy number
- emergency department
- high throughput
- adverse drug
- poor prognosis
- genome wide
- deep learning
- single cell
- artificial intelligence
- data analysis
- free survival
- young adults
- childhood cancer
- replacement therapy